EXAMINE THIS REPORT ON LINK ALTERNATIF MBL77

Besides ibrutinib, patients with M-CLL, devoid of TP53 aberrations and in good shape sufficient to tolerate FCR therapy, should be superior candidates with the latter, While using the benefit currently being that this therapy can be accomplished in 6 months when ibrutinib has to be taken indefinitely. This feature might be specially beneficial for